keyword
MENU ▼
Read by QxMD icon Read
search

Montelukast asthma

keyword
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#1
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29726704/cysteinyl-leukotriene-receptor-antagonists-induce-apoptosis-and-inhibit-proliferation-of-human-glioblastoma-cells-by-down-regulating-b-cell-lymphoma-2-and-inducing-cell-cycle-arrest
#2
Pannaree Piromkraipak, Tipparat Parakaw, Suttinee Phuagkhaopong, Sirada Srihirun, Sukumal Chongthammakun, Kulathida Chaithirayanon, Pornpun Vivithanaporn
Glioblastoma is the most aggressive type of brain cancer with the highest proliferation, invasion and migration. Montelukast and zafirlukast, two widely used leukotriene receptor antagonists (LTRAs) for asthma treatment, inhibited invasion and migration of glioblastoma cell lines. Montelukast induces apoptosis and inhibites cell proliferation of various cancer cells. Herein, apoptotic and antiproliferative effects of montelukast and zafirlukast were investigated in two glioblastoma cell lines, A172 and U-87 MG...
May 4, 2018: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/29708817/montelukast-inhibits-hypoxia-inducible-factor-1%C3%AE-translation-in-prostate-cancer-cells
#3
Caixia Tang, Hu Lei, Jinfu Zhang, Meng Liu, Jin, Hao Luo, Hanzhang Xu, Yingli Wu
Through regulating the expression of hundreds of genes, hypoxia-inducible factor -1(HIF-1) plays a critical role in hypoxic adaption of cancer cells and is considered as a target for cancer therapy. Here we show that montelukast, a clinical leukotriene receptor antagonist for the treatment of asthma, inhibits hypoxia or CoCl2 -induced HIF-1α activation and reduces its protein expression in prostate cancer cells. However, the other two leukotriene receptor antagonists, pranlukast and zafirlukast, cannot decrease HIF-1α protein, which indicates that montelukast-induced downregulation of HIF-1α is not mediated by leukotriene receptor...
April 30, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29704475/chronic-cough-related-to-acute-viral-bronchiolitis-in-children-chest-expert-panel-report
#4
Anne B Chang, John J Oppenheimer, Bruce K Rubin, Miles Weinberger, Richard S Irwin
BACKGROUND: Acute bronchiolitis is common in young children and some children develop chronic cough after their bronchiolitis. We thus undertook systematic reviews based on key questions (KQs) using the PICO format. The KQs were: Among children with chronic cough (>4 weeks) after acute viral bronchiolitis, how effective are the following interventions in improving the resolution of cough?: (1) Antibiotics. If so what type and for how long? (2) Asthma medications (inhaled steroids, beta2 agonist, montelukast) and; (3) Inhaled osmotic agents like hypertonic saline? METHODS: We used the CHEST expert cough panel's protocol and the American College of Chest Physicians (CHEST) methodological guidelines and GRADE framework...
April 25, 2018: Chest
https://www.readbyqxmd.com/read/29685001/cysteinyl-leukotrienes-c4-and-d4-downregulate-human-mast-cell-expression-of-toll-like-receptors-1-through-7
#5
V Karpov, R Ilarraza, A Catalli, M Kulka
Cysteinyl leukotrienes (CysLT) are potent inflammatory lipid molecules that mediate some of the pathophysiological responses associated with asthma such as bronchoconstriction, vasodilation and increased microvascular permeability. As a result, CysLT receptor antagonists (LRA), such as montelukast, have been used to effectively treat patients with asthma. We have recently shown that mast cells are necessary modulators of innate immune responses to bacterial infection and an important component of this innate immune response may involve the production of CysLT...
March 2018: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/29643544/-bronchial-adenoid-cystic-carcinoma-masquerading-as-bronchial-asthma-a-case-report
#6
M Lu, M Wang, X Zhu, Y H Chen, W Z Yao
Here we reported a case of bronchial adenoid cystic carcinoma from Peking University Third Hospital. A 40-year-old female presented with dry cough for 1 year and nocturnal paroxysmal attacks of wheezing for 4 months. She was a non-smoker, and did not have past histories of asthma or allergy. On physical examination, no stridor, wheezing and cyanosis were present and the general appearance was good. The results of the laboratory analysis, including blood eosinophils count, immunoglobulin E level and chest X-ray were normal...
April 18, 2018: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29582642/leukotriene-receptor-antagonists-inhibit-mitogenic-activity-in-triple-negative-breast-cancer-cells
#7
Kran Suknuntha, Ruedeemars Yubolphan, Kanokpan Krueaprasertkul, Sirada Srihirun, Nathawut Sibmooh, Pornpun Vivithanaporn
Despite a discovery of hormonal pathways regulating breast cancer, a definitive cure for the disease requires further identification of alternative targets that provide a hormone-independent support. Apart from their role in inflammatory diseases, cysteinyl leukotriene (CysLT) receptor antagonists (LTRAs) decrease the risk of lung cancer in asthma patients and inhibit tumor progression in several malignancies. In the present study, we evaluate the effects of two chemically different, clinically relevant LTRAs (montelukast and zafirlukast) in a triple negative breast cancer cell line, MDAMB- 231...
March 27, 2018: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29559484/extracorporeal-membrane-oxygenation-ecmo-for-near-fatal-asthma-refractory-to-conventional-ventilation
#8
Usman Maqsood, Nehal Patel
We describe a case of near-fatal asthma, treated successfully by initiation of extracorporeal membrane oxygenation (ECMO). A 29-year-old woman, known asthmatic on steroid inhalers, inhaled/nebulised bronchodilators, long-term oral prednisolone, theophylline and montelukast, presented with acute shortness of breath. She deteriorated following initial treatment with nebulised bronchodilators and magnesium sulfate requiring intubation and mechanical ventilation. Severe bronchospasm ensued following mechanical ventilation and peak airway pressures remained at 55 cm H2 O with intrinsic positive end expiratory pressure(PEEP) of 14 cm H2 O...
March 20, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29518425/leukotriene-e-4-induces-airflow-obstruction-and-mast-cell-activation-via-the-cyslt-1-receptor
#9
Nikolaos Lazarinis, Johan Bood, Cristina Gomez, Johan Kolmert, Ann-Sofie Lantz, Pär Gyllfors, Andy Davis, Craig E Wheelock, Sven-Erik Dahlén, Barbro Dahlén
BACKGROUND: Leukotriene E4 (LTE4 ) is the final active metabolite among the cysteinyl leukotrienes (CysLTs). Animal studies have identified a distinct LTE4 receptor, suggesting that current CysLT1 receptor antagonists may provide incomplete inhibition of CysLT responses. OBJECTIVE: We tested this hypothesis by assessing the influence of the CysLT1 antagonist montelukast on responses induced by inhalation of LTE4 in asthmatic subjects. METHODS: Fourteen subjects with mild intermittent asthma and two subjects with aspirin exacerbated respiratory disease (AERD) received montelukast 20 mg bid and placebo for 5-7 days in a randomized, double blind, crossover study (NCT01841164)...
March 5, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29493871/montelukast-reverses-airway-remodeling-in-actively-sensitized-young-mice
#10
Stephane Debelleix, Valérie Siao-Him Fa, Hugues Begueret, Patrick Berger, Andy Kamaev, Olga Ousova, Roger Marthan, Michael Fayon
Asthma is characterized by airway hyperresponsiveness (AHR) and inflammation leading to airway remodeling (AR). In children, AR may occur very early prior to the age of 6 years. Treatments to prevent or reverse AR are unknown. AIM: We sought to determine (i) whether short allergenic sensitization at a young age in a mouse model may induce enhanced AR and inflammation compared to adults; (ii) the effect of Montelukast on such AR. METHODS: Immature and adult Balb/c mice were sensitized and challenged with ovalbumin...
March 1, 2018: Pediatric Pulmonology
https://www.readbyqxmd.com/read/29438596/early-discontinuation-of-montelukast-treatment-a-danish-nationwide-utilization-study
#11
Rahmo I Farah, Per Damkier, Anders Christiansen, Daniel P Henriksen
Montelukast, a leukotriene receptor antagonist, was marketed in 1998 as an oral supplementary treatment to patients with mild to moderate asthma. The aim of this study was to describe the early discontinuation pattern among montelukast users in Denmark in the period of 1 March 1998 to 31 December 2016, and to identify demographic characteristics possibly associated with early discontinuation. This nationwide drug utilization study was based on data collected from three nationwide Danish registers. All montelukast users who redeemed at least one prescription in the study period were identified...
February 13, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29432192/cysteinyl-leukotriene-receptor-1-antagonism-prevents-experimental-abdominal-aortic-aneurysm
#12
Antonio Di Gennaro, Ana Carolina Araújo, Albert Busch, Hong Jin, Dick Wågsäter, Emina Vorkapic, Kenneth Caidahl, Per Eriksson, Bengt Samuelsson, Lars Maegdefessel, Jesper Z Haeggström
Cysteinyl-leukotrienes (cys-LTs) are 5-lipoxygenase-derived lipid mediators involved in the pathogenesis and progression of inflammatory disorders, in particular asthma. We have previously found evidence linking these mediators to increased levels of proteolytic enzymes in tissue specimens of human abdominal aortic aneurysm (AAA). Here we show that antagonism of the CysLT1 receptor by montelukast, an established antiasthma drug, protects against a strong aorta dilatation (>50% increase = aneurysm) in a mouse model of CaCl2 -induced AAA at a dose comparable to human medical practice...
February 20, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29413502/efficacy-and-safety-of-lebrikizumab-in-adult-patients-with-mild-to-moderate-asthma-not-receiving-inhaled-corticosteroids
#13
Philip Korenblat, Edwin Kerwin, Igor Leshchenko, Karl Yen, Cecile T J Holweg, Judith Anzures-Cabrera, Carmen Martin, Wendy S Putnam, Laura Governale, Julie Olsson, John G Matthews
BACKGROUND: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma. In a previous Phase 2 study, lebrikizumab, an anti-IL-13 monoclonal antibody, did not significantly improve FEV1 in mild-to-moderate asthma patients not receiving ICS therapy. This Phase 3 study was designed to further assess the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma treated with daily short-acting β2 -agonist therapy alone...
January 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29406838/real-world-characteristics-and-treatment-patterns-in-patients-with-urticaria-initiating-omalizumab-in-the-united-states
#14
Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Liya Wang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized. OBJECTIVE: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world...
December 19, 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29390493/traditional-chinese-medicine-as-an-adjunctive-therapy-to-oral-montelukast-for-treating-patients-with-chronic-asthma
#15
RANDOMIZED CONTROLLED TRIAL
Xuehui Wang, Ziting Tian, Fengli Gao, Xia Zhang, Jianqiu Liu, Zhuying Li
BACKGROUND: This study aimed to explore the efficacy and safety of Ping Chuan Ke Li (PCKL) as an adjunctive therapy to oral montelukast compared with placebo plus montelukast for treating patients with chronic asthma (CAS). METHODS: This randomized controlled trial involved 72 patients with CAS. They were randomly allocated to an intervention group or a control group, 36 subjects per group. Participants in the intervention group received PCKL and oral montelukast, while those in the control group received placebo and oral montelukast...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29375702/clinical-efficacy-of-recombinant-human-latrophilin-3-antibody-in-the-treatment-of-pediatric-asthma
#16
Maohua Liu, Jingxiu Zhang, Chengjun Liu
Pediatric asthma is a chronic pulmonary inflammatory disease featuring hypersecretion of mucus and inflammation in the airway, resulting in dysfunction of the airway smooth muscle. Previous evidence demonstrated that latrophilins, a novel family of receptors, present a beneficial effect on airway smooth muscle cells. In the present study, the therapeutic effects of recombinant human latrophilin 3 (rhLPHN3) antibody (Ab) in patients with pediatric asthma were investigated, and the molecular mechanism underlying the function of LPHN3 in the treatment of asthma in clinical practice was examined...
January 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29319028/comparison-of-oral-montelukast-with-oral-ozagrel-in-acute-asthma-a-randomized-double-blind-placebo-controlled-study
#17
Rahul Magazine, Vyshak Uddur Surendra, Bharti Chogtu
BACKGROUND: The need for more effective management of acute asthma has led to research on drugs which are otherwise approved for use in chronic asthma. OBJECTIVE: To study and compare the effects of oral montelukast with oral ozagrel in acute asthma. MATERIALS AND METHODS: One hundred and twenty patients with acute asthma were recruited for the study. Out of 120 study patients, forty each were randomized into placebo, montelukast, and ozagrel groups...
January 2018: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/29312540/cyslt1-receptor-antagonist-alleviates-pathogenesis-of-collagen-induced-arthritis-mouse-model
#18
Minwen Xu, Ruiyun Hong, Xiaoli Zhang, Hailin Zou, Yi Zhang, Zhiping Hou, Liefeng Wang
Cysteinyl leukotrienes (CysLTs) play a key role in inflammatory diseases such as asthma and their receptors' antagonists are currently used as anti-asthmatic drugs. CysLTs have also been found to participate in other inflammatory reactions. Here, we reported that in rheumatoid arthritis (RA) animals model, collagen-induced arthritis, (CIA), CysLT1, a receptor for CysLTs, was up-regulated in hind paw and lymph node, while CysLTs levels in the blood were also higher than normal mice. Montelukast, a drug targeting CysLT1, has been shown to effectively reduce the CIA incidence, peak severity, and cumulative disease scores...
December 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29308548/management-of-recurrent-preschool-doctor-diagnosed-wheeze
#19
REVIEW
Ka-Ka Siu, Shuk-Yu Leung, Sum-Yi Kong, Daniel Kwok-Keung Ng
Preschool wheeze occurs in half of the children before they reach 6 y of age and recurrence is also common. Recurrent preschool wheeze is classified as either typical or atypical. For typical recurrent preschool wheeze, the diagnoses are either asthma or bronchiolitis/bronchitis. Responsiveness to a properly administered bronchodilator confirms asthma, atopic or otherwise. All atypical preschool wheeze should be referred to pediatric respirologist for assessment. Lung function test by impulse oscillometry (IOS) before and after bronchodilator is helpful to confirm airway hyperresponsiveness, an essential feature of asthma...
January 8, 2018: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/29248523/emerging-therapies-for-atopic-dermatitis-the-prostaglandin-leukotriene-pathway
#20
Daniel A Yanes, Joy L Mosser-Goldfarb
The role of leukotrienes and prostaglandins in development of atopy has been prototypically established in studies of asthma pathogenesis. Likewise, both in vitro and in vivo studies of atopic dermatitis have demonstrated that these molecules maintain important pathophysiologic roles. Thus, it follows that targeted therapies against these molecules may be promising in management of atopic dermatitis. Montelukast has had questionable efficacy in patients with atopic dermatitis, whereas small pilots using zileuton did have some clinically significant improvement...
March 2018: Journal of the American Academy of Dermatology
keyword
keyword
33625
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"